OABI earnings analysis
What we found in OABI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
OmniAb, Inc. reported strong Q1 2026 results with revenues of $14.4 million, a significant increase from $4.2 million in the prior year, and an EPS loss of -$0.06, outperforming expectations. The company raised its full-year revenue guidance to between $28 million and $33 million, reflecting robust developments in its partner programs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Up 247% YoY
- Q1 2026 revenue reached $14.4 million, up from $4.2 million in Q1 2025.
- EPS Loss Narrowed
- Reported EPS loss was -$0.06, compared to -$0.17 in Q1 2025.
- Significant Milestone Revenue Growth
- License and milestone revenue surged to $12.0 million from $2.0 million, a 495% increase.
- Improvement in Operating Cash Flow
- Operating cash flow improved to -$4.9 million from -$15.9 million in Q1 2025.
- Cost Management Success
- Research and development expenses decreased by 24% year-over-year to $9.64 million.
- Revised Revenue Guidance
- Full-year revenue guidance raised to $28 million to $33 million, up from $25 million to $30 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Cash Burn Rate
- Cash used in operating activities was $4.9 million, albeit improved from $15.9 million in the prior year.
- Regulatory Risks
- The company is heavily reliant on partners for commercialization and regulatory approvals of drugs.
- Market Acceptance Uncertainties
- Future revenues hinge on partner success in drug development and market acceptance of therapies.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.06
What they said about what is next.
Guidance raised from previous estimates of $25 million to $30 million.
The filing reads better than the one before it.
What came before.
- 10-K · March 4, 2026
- OmniAb positions itself as a multi-species, biologically driven antibody discovery platform that licenses technology to partners and collects access fees, services, milestones and royalties. The company reported a large…
- 10-K · March 18, 2025
- OmniAb positions itself as a platform company that licenses a four‑species transgenic animal and high‑throughput screening stack (OmniAb, OmniDeep, xPloration/GEM) to pharma/biotech partners; as of December 31, 2024 it…
- 10-K · March 25, 2024
- OmniAb positions itself as a partner‑centric antibody discovery platform with a differentiated four‑species technology suite (OmniRat, OmniMouse, OmniChicken, OmniTaur) and new in‑silico/AI tools (OmniDeep launched May…
- 10-Q · August 10, 2023
- OmniAb reported Q2 revenue of $6,946,000 (three months ended June 30, 2023) vs $7,199,000 in the year-ago quarter, with net loss of $14,728,000 (loss per share $0.15). License & milestone revenue rose materially while…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OABI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever